KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Expenses: 2009-2025

Historic Operating Expenses for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $242.9 million.

  • Acadia Pharmaceuticals' Operating Expenses rose 11.03% to $242.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $806.2 million, marking a year-over-year decrease of 1.32%. This contributed to the annual value of $727.0 million for FY2024, which is 9.10% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Operating Expenses of $242.9 million as of Q3 2025, which was up 4.60% from $232.2 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Operating Expenses' 5-year high stood at $269.5 million during Q3 2023, with a 5-year trough of $106.1 million in Q4 2024.
  • Its 3-year average for Operating Expenses is $202.4 million, with a median of $211.5 million in 2024.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Operating Expenses soared by 66.77% in 2023, and later plummeted by 45.89% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Operating Expenses (Quarterly) stood at $175.4 million in 2021, then rose by 4.07% to $182.6 million in 2022, then climbed by 7.42% to $196.1 million in 2023, then slumped by 45.89% to $106.1 million in 2024, then increased by 11.03% to $242.9 million in 2025.
  • Its Operating Expenses was $242.9 million in Q3 2025, compared to $232.2 million in Q2 2025 and $225.0 million in Q1 2025.